A Form 4 filed with the SEC on September 17, 2026 discloses that Robert Glassman, a director of Pharvaris N.V. (NASDAQ:PHVS), executed a cashless stock option exercise and sale of 8,667 shares of common stock on September 15, 2026 pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: 8,667 shares of Pharvaris N.V. common stock disposed of on September 15, 2026.
  • Weighted average sale price: $38.2735 per share, with individual transaction prices ranging from $38.175 to $38.43.
  • Option exercise: 8,667 stock options were exercised at a conversion price of $22.31 per share in connection with the sale.
  • Post-transaction ownership: Glassman directly beneficially owns 10,500 shares of common stock following the reported transactions.
  • 10b5-1 plan: The filing states this is "a scheduled exercise and sale from 10b5-1 trading plan."
  • Remaining derivative securities: Zero stock options remain beneficially owned by the reporting person following the transaction.

Glassman's Cashless Option Exercise and Share Sale at Pharvaris N.V.

According to the filing, Robert Glassman, identified as a director of Pharvaris N.V., carried out two linked transactions on September 15, 2026. First, he exercised 8,667 stock options (transaction code M) at an exercise price of $22.31 per share, acquiring 8,667 shares of common stock. Immediately prior to the exercise, the filing shows his beneficial ownership stood at 19,167 shares directly held.

In the second transaction (transaction code S), Glassman disposed of all 8,667 shares acquired through the option exercise at a weighted average price of $38.2735 per share. The filing notes that "the shares were sold in connection with the exercise of stock options in a cashless exercise transaction" and that sales were executed across multiple transactions at prices ranging from $38.175 to $38.43. Following both transactions, his direct beneficial ownership of common stock stands at 10,500 shares, according to the filing.

The filing further discloses that the exercised stock options carried an expiration date of April 11, 2034, and that "100% of the option vest on the 12-month anniversary." After the exercise, zero stock options remain in Glassman's beneficial ownership. The form was signed by Marnus Nel as Attorney-in-Fact for Robert Glassman and was filed on September 17, 2026. The filing indicates the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

What Was Disclosed

The Form 4 discloses a cashless exercise of 8,667 Pharvaris N.V. stock options and an equivalent sale of shares by director Robert Glassman on September 15, 2026, conducted under a pre-established Rule 10b5-1 trading plan, leaving him with 10,500 directly held shares.